Updating results

205 results

Sort: Relevance | Date

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

Technology appraisal guidance Published July 2013 Last updated October 2018

Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Technology appraisal guidance Published September 2009 Last updated March 2017

Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)

Evidence-based recommendations on lenalidomide (Revlimid) for the treatment of multiple myeloma in people who have received at least 2 prior therapies

Technology appraisal guidance Published June 2009 Last updated June 2019

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance Published September 2014 Last updated June 2019

Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2010 Last updated August 2017

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated October 2018

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Technology appraisal guidance Published March 2011 Last updated June 2018

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..

Technology appraisal guidance Published December 2011 Last updated March 2017

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC

Technology appraisal guidance Published January 2020

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults

Technology appraisal guidance Published March 2019

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma

Technology appraisal guidance Published January 2019

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up 25 years

Technology appraisal guidance Published December 2018

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in

Technology appraisal guidance Published June 2018

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults

Technology appraisal guidance Published March 2018

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published January 2017 Last updated September 2017

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older

Technology appraisal guidance Published December 2019

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer

Technology appraisal guidance Published November 2019

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease

Technology appraisal guidance Published October 2019

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung

Technology appraisal guidance Published September 2019

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults

Technology appraisal guidance Published September 2019

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a

Technology appraisal guidance Published August 2019 Last updated February 2020

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

Technology appraisal guidance Published August 2019

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced

Technology appraisal guidance Published August 2019

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults

Technology appraisal guidance Published August 2019

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

Technology appraisal guidance Published July 2019

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults

Technology appraisal guidance Published June 2019

Cladribine for treating relapsing–remitting multiple sclerosis (TA616)

Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults

Technology appraisal guidance Published December 2019

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older

Technology appraisal guidance Published December 2019

Venetoclax for treating chronic lymphocytic leukaemia (TA487)

Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published November 2017

Aflibercept for treating choroidal neovascularisation (TA486)

Evidence-based recommendations on aflibercept (Eylea) for treating myopic choroidal neovascularisation in adults

Technology appraisal guidance Published November 2017

Sarilumab for moderate to severe rheumatoid arthritis (TA485)

Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults

Technology appraisal guidance Published November 2017

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

Technology appraisal guidance Published November 2017

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

Technology appraisal guidance Published November 2017

Immunosuppressive therapy for kidney transplant in children and young people (TA482)

Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people

Technology appraisal guidance Published October 2017

Immunosuppressive therapy for kidney transplant in adults (TA481)

Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults

Technology appraisal guidance Published October 2017

Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis (rheumatism) in adults

Technology appraisal guidance Published October 2017

Reslizumab for treating severe eosinophilic asthma (TA479)

Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults

Technology appraisal guidance Published October 2017

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

Technology appraisal guidance Published October 2017

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

Technology appraisal guidance Published October 2017

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for untreated metastatic pancreatic cancer in adults

Technology appraisal guidance Published September 2017

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published September 2017

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Technology appraisal guidance Published July 2019

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Technology appraisal guidance Published July 2019